key: cord-0714758-66xcvveg authors: FitzGerald, Richard; Dickinson, Laura; Else, Laura; Fletcher, Thomas; Hale, Colin; Amara, Alieu; Walker, Lauren; Penchala, Sujan Dilly; Lyon, Rebecca; Shaw, Victoria; Greenhalf, William; Bullock, Katie; Lavelle-Langham, Lara; Reynolds, Helen; Painter, Wendy; Holman, Wayne; Ewings, Sean; Griffiths, Gareth; Khoo, Saye title: Pharmacokinetics of ß-d-N4-hydroxycytidine, the parent nucleoside of prodrug molnupiravir, in non-plasma compartments of patients with SARS-CoV-2 infection date: 2022-03-10 journal: Clin Infect Dis DOI: 10.1093/cid/ciac199 sha: b1711251fd9fbad6b1c4468cf329cc1b393b2856 doc_id: 714758 cord_uid: 66xcvveg ß-d-N4-hydroxycytidine (NHC), the parent nucleoside of molnupiravir, a COVID-19 antiviral, was quantified at sites of SARS-CoV-2 transmission in twelve patients enrolled in AGILE CST-2 (NCT04746183). Saliva, nasal and tear concentrations were 3, 21 and 22% that of plasma. Saliva and nasal NHC concentrations were significantly correlated with plasma (p<0.0001). An extended therapeutic goal of antiviral therapy is the prevention of infection in individuals that have been exposed to an infected person. SARS-CoV-2 infection occurs through inhalation or inoculation of virus onto upper respiratory airways and mucosal surfaces and in order to be an effective prophylactic agent, drug must penetrate into these sites in sufficient quantities. Molnupiravir (EIDD-2801; MK-4482), a prodrug of the ribonucleoside analogue 14 β-d-N4hydroxycytidine (NHC), has recently been licensed in the UK and received FDA Emergency Use Authorisation (EUA) in the US for the treatment of symptomatic COVID-19 in adults with at least one risk factor for developing severe disease. Following oral administration, molnupiravir is rapidly hydrolysed by esterases to NHC, which is phosphorylated by host kinases to active intracellular metabolite EIDD-1931-5'-triphosphate (EIDD-2061) [1] . AGILE, a UK platform for early-phase trials of novel COVID-19 therapies [2] , has evaluated molnupiravir within its AGILE Candidate-Specific Trial (CST)-2 seamless phase Ib/IIa protocol. We previously reported phase Ib evaluation of molnupiravir across three dosing arms (300, 600 and 800 mg twice daily), establishing that 800 mg twice daily for 5 days was suitable for progression to phase II [3] , which is currently recruiting. We report here the pharmacokinetics of molnupiravir and NHC in saliva, nasal secretions and tears, in comparison with plasma concentrations within AGILE CST-2 Ib. M a n u s c r i p t 4 Molnupiravir pharmacokinetics were evaluated as part of a phase I dose-escalation study (300, 600, 800 mg twice daily) in patients with PCR-confirmed SARS-CoV-2 infection, within 5 days of symptom onset and presenting with mild or moderate disease (NCT04746183). The study design has previously been described [3] and further details can be found in the Supplementary Material. Plasma and non-plasma (saliva, nasal secretions and tears) samples were collected at predose, 0.5, 1, 2, and 4 hours post-dose on study days 1 and 5. Plasma samples were collected as previously described [4] . Non-plasma sample collections and molnupiravir dosing conditions are described in the Supplementary Material. Molnupiravir and NHC concentrations were determined at the University of Liverpool Bioanalytical Facility (Liverpool, UK). Plasma and saliva concentrations were quantified using a validated LC-MS method [4] . NHC in nasal secretions and tears (swabs) were determined using an adaptation of this method described in the Supplementary Material. All assays were validated in accordance with FDA [5] and EMA guidelines [6] . Given the small sample size, representation of the pharmacokinetic data was largely exploratory and descriptive. Samples below the lower limit of quantification (LLQ; <2.5 ng/mL) at pre-dose on day 1 were included as 0 ng/mL; those